ABBV Looks 19.5% Overvalued on GF Value™

AbbVie (NYSE: ABBV) announced a multi-year partnership with Iambic Therapeutics to develop AI-driven small-molecule therapies. Despite a 1% premarket drop, ABBV offers a 2.59% dividend yield with a 62% payout ratio and a 5.2% 3-year growth rate. The stock trades 19.5% above its GF Value™ estimate of $220.80, with a GF Score™ of 76/100. Insiders sold $17.7M in shares, while 18 gurus hold positions with mixed activity.

AbbVie presented new lung cancer research at WCLC 2026, including Phase 1b data for PD-1/VEGF bispecific ABBV-1480 and SEZ6-targeted ADC ABBV-706. ABBV-1480 showed 90% ORR in squamous NSCLC and 75.9% in non-squamous. ABBV-706 showed 80%+ response rates in SCLC. AbbVie's strategy focuses on multimodality therapy and tolerability.

AbbVie (ABBV) reported positive Phase 3 trial results for Qulipta in treating menstrual migraines, potentially expanding its label. Qulipta sales grew 31% YoY to $350M in Q2. AbbVie's growth is primarily driven by Skyrizi and Rinvoq, with combined revenue expected to exceed $31B this year. The company also acquired Apogee Therapeutics for $10.9B, gaining access to zumilokibart, a promising immunology asset.

AbbVie (ABBV) reported positive Phase 3 trial results for Qulipta, a migraine treatment, showing significant reduction in menstrual migraine days. The drug could gain label expansion, targeting a potential U.S. market of over 9 million patients. Qulipta's Q2 sales were $350M, up 31% YoY. AbbVie's growth is primarily driven by Skyrizi and Rinvoq, with combined revenue expected to exceed $31B this year. The company also acquired Apogee Therapeutics for $10.9B, gaining access to zumilokibart, a pro

AbbVie (ABBV) presented new real-world and pediatric safety data for VRAYLAR in treating MDD and bipolar I at Psych Congress 2026. The data covers complex patient groups and younger patients with mood disorders. AbbVie, a biopharmaceutical company with a $466.6b market cap, sees neuroscience as a key growth area, with VRAYLAR playing a role in revenue stability and diversification.

AbbVie presented data at Psych Congress 2026 showing VRAYLAR (cariprazine) improved depressive symptoms and quality of life in real-world studies for MDD and BP-I. The studies involved 118 BP-I and 76 MDD patients, with significant symptom reductions and improved functioning. VRAYLAR is approved for various psychiatric conditions and has been used by over 150,000 clinicians. The company also shared additional research on safety and patient preferences.